We’re thrilled to share some exciting news from Opyl Limited! We’ve just signed a Memorandum of Understanding (MOU) with the Xco consortium, marking a significant step in our global expansion journey. This collaboration will see us teaming up with Whit Pepper and Greg Bailey, along with their extensive team, to form a joint venture (JV) aimed at marketing and distributing Opyl’s innovative products and services, including TrialKey, across Europe, the Middle East, Africa, and North America.
What Does This Mean for Opyl?
This partnership represents a fantastic opportunity for Opyl to broaden its reach and enhance its impact in the clinical trial and biotech sectors. Here’s a closer look at what this means for our company and stakeholders:
1. Initial Due Diligence Period
We’re kicking things off with a three-month due diligence period to ensure all terms and conditions are thoroughly agreed upon.
2. Formation of the Joint Venture
Once established, the JV will exclusively market and sell Opyl’s products in the specified regions, providing us with a powerful platform for growth and increased market presence.
3. Financial Boost
Opyl will receive a cash payment of USD 1 million (AUD 1.5 million) upon successful completion of due diligence. This payment will cover license rights and research and development efforts.
4. Capital Raise
The JV entity will undertake a capital raise, targeting between USD 3 million and USD 5 million within nine months of establishment. This funding will support the marketing and sales of our products, ensuring robust growth and market penetration.
5. Revenue Sharing and Equity Stake
Opyl will hold a 20% equity stake in the JV, with a structured revenue-sharing agreement that benefits both parties. For the initial USD 1.25 million of revenue, 80% will go to the JV entity and 20% to Opyl. Revenue exceeding this amount will be split 60% to the JV entity and 40% to Opyl.
About Xco
Whit Pepper has spent thirty years as an executive and advisor to boards and CEOs of highly technical engineering, financial services, technology, and scientific research organizations around the world. He is a US-Australian dual citizen who splits time between living in Texas and London.
Whit specializes in working with professionals offering highly technical, complex solutions to transform their ideas and innovations into compelling propositions and competitive businesses. He has successfully worked with scientists, engineers, researchers, accountants, lawyers, and financiers in more than twenty countries to significantly increase revenue and profitability.
Dr Greg Bailey is an experienced leader and entrepreneur in the biotech industry; he has created over $32 billion in shareholder returns (delivering 200x). Exit transactions have included two of the top ten biggest biotech deals in the last decade. Greg provides strategic advice to Xco on everything from financial structure through to clinical trial design, and he serves as an invaluable resource in bringing in the appropriate experts to undertake due diligence for Xco projects.
The broader team is made of tech, medical, financial, and operations professionals based in North America, Europe, and Asia/Pacific.
Strategic Goals and Sales Targets
The JV has set ambitious revenue targets to ensure its success and maintain exclusivity in the territories:
- Year 1: USD 1 million
- Year 2: USD 2 million
- Year 3: USD 4 million
Meeting these targets will be crucial for maintaining our exclusive rights and driving substantial growth.
Benefits for Opyl and Its Shareholders
This JV offers numerous benefits:
- Revenue Generation: A lucrative revenue stream through cash payments and profit-sharing.
- Market Validation: Validates our technology, attracting more interest and investment.
- Strategic Growth: Accelerates our market penetration with access to new territories.
- Focus on APAC: Allows Opyl to concentrate on expanding in the Asia-Pacific region while the JV handles other major markets.
Looking Ahead
Saurabh Jain, our Executive Chairman, summed it up perfectly:
“This joint venture marks a significant milestone for Opyl as we expand our global footprint. Partnering with a knowledgeable and capable entity like Xco consortium validates our technology and opens new avenues for growth and revenue generation. We are excited about the potential this collaboration brings to our shareholders and the broader market.”
